Lurasidone

In the year 2011 FDA give regulatory approval to a new drug molecule " Lurasidone" a second generation Antipsychotic drug intended for Schizophrenia. Lurasidone is an Azapiron Derivative and it exhibits its pharmacological effect by acting on the D2 and Serotonin 5HT 2A Receptors as a complete a antagonist. lurasidone also has high affinity for serotonin 5HT7 and it is a partial agonist at 5HT1A receptor. it is believed that these properties can be potentially related to effects on cognition and mood.

Brands
Adult Dose
Dose: 40 to 80 mg
Single Dose: 60 (60)
Frequency: 24 hourly
Route: PO
Instructions: Should be taken with food.
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to Benzoisothiasole Derivative. It belongs to D2,Serotonin 5HT2A full Antagonist pharmacological group on the basis of mechanism of action.
Contraindications
Lurasidone is contraindicated in conditions like Hypersensitivity to the drug.
Effects
Lurasidone produces potentially life-threatening effects which include Seizures, Suicidal ideation, mortality in elderly patient with dementia. which are responsible for the discontinuation of Lurasidone therapy.The signs and symptoms that are produced after the acute overdosage of Lurasidone include Somnolence, parkinsonism, Akathisia, elevation of creatinine, Dystonia.The symptomatic adverse reactions produced by Lurasidone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Akathisia, Agitation, Orthostatic hypotension, Weight changes.
Indications
Lurasidone is primarily indicated in conditions like Psychosis, Schizophrenia.
Interactions
No data regarding the interactions of Lurasidone was found.
Interfrence
Risks
Drug should not be given to Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Dose should not exceed 40mg in patients of severe Renal impairment and with moderate-severe hepatic impairment. Greater frequency of parkinsinism and dsytonia , when dose increase to 120mg/d It should be taken with precaution in pregnancy
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.